Today, Eli Lilly and Co. (LLY) Receives Outperform Rating from Leerink Swann

Today, Eli Lilly and Co. (LLY) Receives Outperform Rating from Leerink Swann

Leerink Swann reiterated their outperform rating on shares of Eli Lilly and Co. (NYSE:LLY) in a research report released on Saturday morning. Leerink Swann currently has a $92.00 price objective on the stock, down from their previous price objective of $102.00.

Several other research firms have also commented on LLY. Argus boosted their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a buy rating in a research report on Tuesday, August 2nd. Morgan Stanley set a $73.00 target price on shares of Eli Lilly and and gave the company a hold rating in a report on Thursday. Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $92.00 target price on the stock in a report on Friday, August 5th. BMO Capital Markets restated an outperform rating and issued a $94.00 target price on shares of Eli Lilly and in a report on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a neutral rating to a buy rating and upped their target price for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $108.34.

Eli Lilly and (NYSE:LLY) traded up 1.65% on Friday, hitting $69.12. 8,620,682 shares of the stock traded hands. The stock has a market cap of $73.11 billion, a price-to-earnings ratio of 30.07 and a beta of 0.28. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $88.16. The firm’s 50-day moving average price is $76.69 and its 200-day moving average price is $77.92.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the consensus estimate of $0.96 by $0.08. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business earned $5.19 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter in the prior year, the firm earned $0.89 earnings per share. Eli Lilly and’s quarterly revenue was up 4.7% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and will post $3.55 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s dividend payout ratio (DPR) is currently 88.70%.

In other news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock valued at $4,979,889,000 after buying an additional 1,350,329 shares during the period. Franklin Resources Inc. boosted its position in shares of Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock valued at $2,238,939,000 after buying an additional 685,898 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in shares of Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock valued at $2,100,581,000 after buying an additional 289,681 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock valued at $1,825,790,000 after buying an additional 668,184 shares during the period. Finally, BlackRock Fund Advisors boosted its position in shares of Eli Lilly and by 2.5% in the third quarter. BlackRock Fund Advisors now owns 17,629,570 shares of the company’s stock valued at $1,414,949,000 after buying an additional 423,179 shares during the period. Institutional investors own 75.11% of the company’s stock.

Eli Lilly and Company Profile

Related posts

Leave a Comment